AptomixRX

AtomiX is developing first-in-class oral TNFα inhibitors based on a newly discovered binding pocket, combining AI-driven design and human organoid models to deliver safer, more effective therapies for autoimmune and inflammatory diseases.

Artificial intelligence.

Physicians.